Skip to main content
SpringerLink
Log in

Bone Lesions in Patients with Chronic Kidney Disease: A Focus on Special Attention on Tetracycline Labeling-Dependent Bone Histomorphometry

  • Chapter
  • First Online:
Osteoporotic Fracture and Systemic Skeletal Disorders

  • 781 Accesses

Abstract

Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) is defined as a systemic disorder of mineral metabolism in CKD that can lead to bone and cardiovascular abnormalities. Renal osteodystrophy (ROD) is now a pathomorphological concept in which bone histology is associated with CKD-MBD. A characteristic for CKD patients is the broad spectra of both bone cell activities and the speed of bone mineralization. Tetracycline labelling-dependent bone histomorphometry is the best tool to assess these two factors. Especially, this morphometry is currently the only tool available to evaluate bone mineralization. However, because the conventional bone histomorphometry has only a limited ability in assessing bone microstructure and cannot evaluate bone material properties at all. Thus, bone histomorphometry is useful, but not all mighty. Therefore, it must not be regarded as the gold standard tool. The spectrum of bone lesions among patients with ROD is likely to have changed over the past 40 years. The tetracycline labelling-dependent bone histomorphometry used today is so sensitive that the major causative factors of the elevated hip fracture risk in dialysis patients must be hidden behind the morphological findings.

The present invited review was completed and submitted to the publisher on 30-May-20. 

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.

    Article  CAS  Google Scholar 

  2. Kazama JJ, Matsuo K, Iwasaki Y, Fukagawa M. Chronic kidney disease and bone metabolism. J Bone Miner Metab. 2015;33:245–52.

    Article  CAS  Google Scholar 

  3. Nortman DF, Coburn JW. Renal osteodystrophy in end-stage renal failure. Postgrad Med. 1978;64:123–30.

    Article  CAS  Google Scholar 

  4. Christov M, Pereira R, Wesseling-Perry K. Bone biopsy in renal osteodystrophy: continued insights into a complex disease. Curr Opin Nephrol Hypertens. 2013;22:210–5.

    Article  CAS  Google Scholar 

  5. Kazama JJ. Bone histology in chronic kidney disease-related mineral and bone disorder. Ther Apher Dial. 2011;15(Suppl 1):23–25.

    Google Scholar 

  6. Ott SM. Histomorphometric measurements of bone turnover, mineralization, and volume. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S151–6.

    Google Scholar 

  7. KDIGO. Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney International Supplements. 2017;7:1–59.

    Google Scholar 

  8. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H, Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y, Tsubakihara Y, Tomo T, Hirakata H, Akizawa T. Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder. Therapeutic Apheresis and Dialysis. 2013;17:247–88.

    Google Scholar 

  9. Kazama JJ, Koda R, Yamamoto S, Narita I, Gejyo F, Tokumoto A. Comparison of quantitative cancellous bone connectivity analyses at two- and three-dimensional levels in dialysis patients. Calcif Tissue Int. 2009;84:38–44.

    Article  CAS  Google Scholar 

  10. Kazama JJ, Koda R, Yamamoto S, Narita I, Gejyo F, Tokumoto A. Cancellous bone volume is an indicator for trabecular bone connectivity in dialysis patients. Clin J Am Soc Nephrol. 2011;5:292–8.

    Article  Google Scholar 

  11. Kazama JJ, Wakasugi M. Parathyroid hormone and bone in dialysis patients. Ther Apher Dial. 2018;22:229–35.

    Article  CAS  Google Scholar 

  12. Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H. Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol. 2012;7:810–19.

    Google Scholar 

  13. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl. 2006;102:S3–7.

    Google Scholar 

  14. D’Haese PC, Couttenye MM, Lamberts LV, Elseviers MM, Goodman WG, Schrooten I, Cabrera WE, De Broe ME. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem. 1999;45:1548–56.

    Article  Google Scholar 

  15. Ackrill P, Day JP, Ahmed R. Aluminum and iron overload in chronic dialysis. Kidney Int Suppl. 1988;24:S163–7.

    CAS  PubMed  Google Scholar 

  16. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26:1368–76.

    Article  Google Scholar 

  17. Wakasugi M, Kazama JJ, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Narita I. Increased risk of hip fracture among Japanese hemodialysis patients. J Bone Miner Metab. 2013;31:315–21.

    Article  Google Scholar 

  18. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:396–9.

    Article  CAS  Google Scholar 

  19. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis. 2006;47:149–56.

    Article  Google Scholar 

  20. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis outcomes and practice patterns study. Kidney Int. 2006;70:1358–66.

    Article  CAS  Google Scholar 

  21. Kazama JJ, Iwasaki Y, Fukagawa M. Uremic osteoporosis. Kidney Int Suppl. 2011;3:446–50.

    Google Scholar 

  22. Iwasaki Y, Kazama JJ, Yamato H, Matsugaki A, Nakano T, Fukagawa M. Altered material properties are responsible for bone fragility in rats with chronic kidney injury. Bone. 2015;81:247–54.

    Article  Google Scholar 

  23. Moe SM. Renal osteodystrophy or kidney-induced osteoporosis? Curr Osteoporos Rep. 2017;15:194–7.

    Article  Google Scholar 

  24. Wakamatsu T, Iwasaki Y, Yamamoto S, Matsuo K, Goto S, Narita I, Kazama JJ, Ito A, Ozasa R, Nakano T, Miyakoshi C, Onishi Y, Fukuma S, Fukuhara S, Yamato H, Fukagawa M, Akizawa T. Type-I angiotensin II receptor blockade reduces uremiainduced deterioration of bone material properties. J Bone Miner Res. 2021;36:67–79.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology and Hypertension, Fukushima Medical University, Fukushima, Japan

    Junichiro James Kazama

Authors
  1. Junichiro James Kazama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junichiro James Kazama .

Editor information

Editors and Affiliations

  1. Niigata Bone Science Institute, Niigata Rehabilitation Hospital, Niigata, Japan

    Hideaki E. Takahashi

  2. Department of Anatomy, Cell Biology and Physiology, Indiana Center for Musculoskeletal Health, Indiana University School of Medicine, Indianapolis, IN, USA

    David B. Burr

  3. Niigata Bone Science Institute, Niigata Rehabilitation Hospital, Niigata, Japan

    Noriaki Yamamoto

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kazama, J.J. (2022). Bone Lesions in Patients with Chronic Kidney Disease: A Focus on Special Attention on Tetracycline Labeling-Dependent Bone Histomorphometry. In: Takahashi, H.E., Burr, D.B., Yamamoto, N. (eds) Osteoporotic Fracture and Systemic Skeletal Disorders. Springer, Singapore. https://doi.org/10.1007/978-981-16-5613-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-981-16-5613-2_19

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-16-5612-5

  • Online ISBN: 978-981-16-5613-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation